AMRI Appoints Dr. Michael A. Guaciaro to Lead New Division
News Mar 02, 2006
Albany Molecular Research, Inc. has announced that Michael A. Guaciaro, Ph.D. has assumed leadership responsibility for the Hungarian facilities, and is relocating to Budapest.
ComGenex Chief Executive Officer Laszlo Urge, Ph.D. will remain with AMRI in Budapest and serve as a key member of the leadership team there.
Since joining AMRI in 2001, Dr. Guaciaro has led over 40 drug discovery project teams and has played a key role in the support and coordination of medicinal chemistry projects at the company's R&D centers in Singapore and India.
Prior to joining AMRI, Dr. Guaciaro worked at American Cyanamid Agricultural Research Center, where he was involved in the integration of research programs between sites in the United States and Europe. He obtained a Ph.D. in organic chemistry from the University of Pennsylvania.
"Dr. Guaciaro is a veteran scientist with 25 years of professional industry experience and has created an impressive record of accomplishment during his tenure at AMRI," said D'Ambra.
"His research teams have discovered and developed several pre-clinical and clinical candidates in a number of therapeutic areas on behalf of our customers."
"We are pleased that Dr. Guaciaro has accepted this exciting opportunity to lead our European operations. I look forward to working closely with him as we continue to integrate ComGenex into the AMRI corporate family."
"We are also pleased that Dr. Urge has agreed to remain with AMRI. His experience and leadership will be critical, both during the short-term transition period and in helping us to achieve our long-range goals."
"He will be working closely with Dr. Guaciaro and the scientific team in Budapest to make this a successful effort."
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Comments | 0 ADD COMMENT
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018